ARDELYX, INC. Derivative Liability, Fair Value, Gross Liability
ARDELYX, INC. (ARDX) had Derivative Liability, Fair Value, Gross Liability of $1.38 billion as of 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2021-03-08
- 2020-12-31: Derivative Liability, Fair Value, Gross Liability $1.38B.
- 2020-09-30: Derivative Liability, Fair Value, Gross Liability $1.26M.
- 2020-06-30: Derivative Liability, Fair Value, Gross Liability $1.12M.
- 2020-03-31: Derivative Liability, Fair Value, Gross Liability $1.05M.
| Period end | Derivative Liability, Fair Value, Gross Liability | Derivative Liability, Fair Value, Gross Liability as first filed |
|---|---|---|
| 2020-12-31 | $1.38B 10-K · filed 2021-03-08 | |
| 2020-09-30 | $1.26M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.12M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $1.05M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $969.00M 10-K · filed 2021-03-08 | $969.00K 10-Q · filed 2020-05-07 |
| 2019-09-30 | $779.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $594.00K 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $570.00K 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $533.00M 10-K · filed 2021-03-08 | $533.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |